Progenics Pharma (PGNX) Misses Q2 EPS by 3c; Sees AZEDRA NDA in August

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Progenics Pharma (PGNX) Misses Q2 EPS by 3c; Sees AZEDRA NDA in August

Progenics Pharmaceuticals Announces Second Quarter 2017 Financial Results and Business Update

August 9, 2017 7:30 AM EDT

NDA (New Drug Application) for AZEDRA® Expected to be Submitted to U.S. Food and Drug Administration (FDA) in August 2017Results from Phase 2b Study of AZEDRA Accepted for Oral Presentation on September 1st at 2017 International Symposium on Pheochromocytoma and Paraganglioma (ISP)Data Highlighting Potential Utility of Automated Bone Scan Index (aBSI) Presented at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in JuneEnrollment Ongoing in Clinical Trials for Prostate Cancer Product Candidates 1404, PyL, and 1095Second Quarter 2017 RELISTOR® Net Sales of $17.3 Million

NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Progenics... More